Cancers 2013, 5(3), 919-942; doi:10.3390/cancers5030919
Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies
1
Department of Experimental and Clinical Sciences, University 'G. d'Annunzio', I-66013 Chieti, Italy
2
Hospital Pharmacy, "SS. Annunziata" Hospital, I-66013 Chieti, Italy
3
Oncology Department, "SS. Annunziata" Hospital, I-66013 Chieti, Italy
*
Author to whom correspondence should be addressed.
Received: 22 April 2013 / Revised: 3 July 2013 / Accepted: 12 July 2013 / Published: 25 July 2013
(This article belongs to the Special Issue Cancer Epigenetics)
Abstract
Hydroxamate-based histone deacetylase inhibitors (Hb-HDACIs), such as vorinostat, belinostat and panobinostat, have been previously shown to have a wide range of activity in hematologic malignancies such as cutaneous T-cell lymphoma and multiple myeloma. Recent data show that they synergize with a variety of cytotoxic and molecular targeted agents in many different solid tumors, including breast, prostate, pancreatic, lung and ovarian cancer. Hb-HDACIs have a quite good toxicity profile and are now being tested in phase I and II clinical trials in solid tumors with promising results in selected neoplasms, such as hepatocarcinoma. This review will focus on their clinical activity and safety in patients with advanced solid neoplasms. View Full-TextKeywords:
hydroxamate-based histone deacetylase inhibitors; histone deacetylase inhibitors; vorinostat; belinostat; panobinostat; pracinostat; abexinostat; resminostat
▼
Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).
Share & Cite This Article
MDPI and ACS Style
Grassadonia, A.; Cioffi, P.; Simiele, F.; Iezzi, L.; Zilli, M.; Natoli, C. Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies. Cancers 2013, 5, 919-942.